The process is not much different. They went forward in the United States; they decided to go for an unadjuvanted vaccine. I can't speak to the details they have. The manufacturers clearly had provided them with sufficient information for them to make a strain change from their seasonal vaccine into their pandemic vaccine, and so that enabled them to license early. But licensing is quite a different thing from actually producing sufficient vaccine for general use. The fact that they can license something doesn't necessarily mean that they have enough material to produce.
In Canada, though, we were actually going for this. We can only work on the data that are submitted to us. The regulator has to wait for data to come in from the manufacturer. As we've just discussed a few minutes ago, we were waiting for data to come in before we could actually license this product.
If there were a situation in Canada, for example, where this disease got really severe in September, then an emergency use order would likely have been instigated, run into an order. You really have to balance the absolute need for the product, in this case for the pandemic early on, versus waiting for data. I think you judge it by how much information you really need, and then you balance what the need is for the vaccine and move forward.